Apoptosis in Medical Technology

Senesco Announces H1N1 Influenza Survival Test Results in Mice

... underscore Factor 5A's ability to mitigate apoptosis caused by inflammation, in this case from the ... is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases ...

Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting

... Small molecule pan-bcl-2 inhibitor AT-101 induces apoptosis in NSCLC by upregulating noxa and enhances ... Mcl-1 inhibition) that has been shown to induce apoptosis directly by operating as a BH3 mimetic and ... lowers the threshold for cancer cells to undergo apoptosis in various tumor types. In Phase I and Phase II ...

Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer

... to date suggest that stimulating cancer cell apoptosis through Bcl-2 pathways with AT-101 may in fact ... the expression of proteins that inhibit apoptosis (programmed cell death). The most recognized ... that has been shown to directly induce apoptosis by operating as a BH3 mimetic and indirectly as ...

Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference

... any product in development that targets the TRAIL apoptosis pathway, and three randomized chemotherapy ... (inhibitor of apoptosis) proteins, thus allowing apoptosis to proceed and causing the cancer cells to die. ... cancer cells, they can help cancer cells resist apoptosis and resume growth and proliferation. ...

Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors

... activity of IAP proteins, thus allowing apoptosis to proceed and causing the cancer cells to die. ... around its leading expertise in the apoptosis pathway. HGS has initiated new chemotherapy ... any product in development that targets the TRAIL apoptosis pathway. About Human Genome Sciences The ...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

... inhibition of the target CRM1 with induction of apoptosis selectively in cancer cells compared to normal ... normal cells by regulating cell growth and apoptosis (cell death). Accumulation of these CRM1 cargo ... leads to the inhibition of cell growth and apoptosis selectively in cancer cells. Kosan's ...

Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor

... 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas," appears in the February ... HDAC inhibitors also appear to promote apoptosis (cell death) in tumor cells. Scientists have been ... of HDAC8 inhibits cell growth and induces apoptosis in cell lines derived from T-cell lymphoma and ...

EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407

... molecule vascular disruption agent (VDA) and apoptosis inducer for the treatment of patients with ... The molecule has been shown to induce tumor cell apoptosis and selectively inhibit growth of proliferating ... Azixa(TM), is part of the EP90745 series of apoptosis inducers, which was licensed by EpiCept to Myriad ...

EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

... through EpiCept's Anti-cancer Screening apoptosis Program (ASAP). EPC2407, a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of cancer patients with ... programmed cell death, which is called apoptosis. apoptosis is normally triggered to destroy a cell from ...

Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)

... with established therapeutics (Abstract 8571) and that TRU-016-mediated apoptosis in CLL cells occurs via a distinct mechanism of apoptosis compared with many other therapeutic agents utilized for the treatment of ...

Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156

... "A Phase 1-2, Multicenter, Open-Label Study of the X- Linked Inhibitor of apoptosis (XIAP) Antisense AEG35156 in Patients with Relapsed or Refractory Chronic ... stage biotechnology company focused on developing drugs that control apoptosis to address major unmet medical needs. In addition to AEG35156, Aegera has ...

Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives

... is the most advanced of any product in development that targets the TRAIL apoptosis pathway. HGS added the new opportunity to develop and commercialize ... two different highly targeted approaches targeting different points in the apoptosis pathway. Each is able to cause cancer cells to die selectively. When IAP ...

Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma

... is a novel, injectable, investigational drug candidate that triggers apoptosis (programmed cell death) in cancer cells. Cancer cells operate at high ... 31, 2007. (10) Kirshner J. Elesclomol (formerly STA-4783) induces apoptosis and enhances the anticancer activity of paclitaxel through induction ...

Senesco Technologies Initiates Preclinical Studies for Cancer Target

... test the ability of Senesco's Factor 5A gene technology to up-regulate apoptosis of cancer cells. Additionally, the studies will evaluate delivery ... those experiments, treatment with Factor 5A caused significant increase in apoptosis of the cancer cells compared to the untreated cells. About Senesco ...

Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC

... by taxanes and other chemotherapeutic agents, and that the reovirus-taxane combination most effectively achieves synergy through accelerated apoptosis triggered by prolonged mitotic arrest. About Oncolytics Biotech Inc. Oncolytics is a Calgary-based biotechnology company focused on the ...

Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting

... a new class of selective, irreversible proteasome inhibitors. Carfilzomib produces specific and sustained inhibition of the proteasome, leading to apoptosis in cancer cells with minimal off-target effects. In Phase 1 and Phase 2 clinical trials, carfilzomib has demonstrated single-agent activity in ...

Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting

... a new class of selective, irreversible proteasome inhibitors. Carfilzomib produces specific and sustained inhibition of the proteasome, leading to apoptosis in cancer cells with minimal off-target effects. In Phase 1 and Phase 2 clinical trials, carfilzomib has demonstrated single-agent activity in ...

Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506

... including VEGFR and TIE2. BAY 73-4506 has also been shown in preclinical studies to prevent the proliferation of tumor cell lines while promoting apoptosis (cell death) by directly targeting several oncogenic TK receptors. The clinical significance of these studies is not known and warrant further ...

Bionovo Announces First Quarter 2009 Highlights and Financial Results

... in April. TspA3 has been identified as an active compound of BN108 that is responsible for BN108's selective cytotoxicity. BN108 and TspA3 induce apoptosis through rapid inactivation of AKT and mTOR kinases in breast cancer cells but not in normal cells. Two additional members joined Bionovo's ...

Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting

... achieving a visual acuity of 20/100. Presumably this permanent decrease in visual acuity is due, in part, to the loss of photoreceptors since apoptosis is a clear consequence of detachment and can continue at low levels even after the retina is reattached. While there have been numerous attempts ...

Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas

... annual meeting in Boston this week on March 9, 2009. The presentation, entitled, "An Orally Available Syk Tyrosine Kinase Inhibitor Induces apoptosis in Peripheral T-Cell Lymphomas Overexpressing Activated Syk" suggested that Syk may play a critical role in some PTCLs and represents a feasible ...

Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2

... activity. The CK2 protein kinase plays a multifunctional role in cell cycle regulation, signal transduction, transcriptional control, angiogenesis, apoptosis and inflammation. Because CK2 contributes to the cancer phenotype via multiple cellular events, CX-4945 has been designed with the objective of ...

Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium

... -- Abstract #85: Poster -- MLN4924, a potent and novel small molecule inhibitor of Nedd8 activating enzyme, induces DNA re-replication and apoptosis in cultured human tumor cells -- Lead investigator: Michael Millhollen, Scientist, Millennium -- Abstract #356: Poster MLN8237 This ...

Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting

... RDEA119 has shown potential as a potent and selective inhibitor of MEK, which is believed to play an important role in cancer cell proliferation, apoptosis and metastasis. Preclinical and clinical results suggest that RDEA119 has favorable properties, including oral dosing, excellent selectivity and ...

Resveratrol Longevity Science Makes Dramatic U-Turn, But Resveratrol Supplements Remain Unchanged

... breast tumor growth in a nude mouse model. Translational Oncology 2008 March; 1(1):19-27; Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Science 2008 May 7; 82(19-20):1032-9] Sardi says other key genes, ...

Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma

... and our TRAIL receptor antibody program," said David C. Stump, M.D., Executive Vice President, Research and Development, HGS. "The TRAIL-mediated apoptosis pathway is an important area of cancer research, and agonistic antibodies to this target offer great promise. HGS-ETR1 is the most advanced of any ...

Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors

... increased potency relative to the well-known PI3 kinase inhibitor LY294002. Both inhibitors demonstrated the ability to significantly induce apoptosis in a renal cell carcinoma cell line (786-0). Evaluation of SF2523 in a 232 kinase panel screen showed that the compound selectively and potently ...

Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines

... cancer therapy. The study demonstrated that the combination of ONCONASE and rosiglitazone synergistically decreased cell viability and increased cell apoptosis in several cancer cell lines, including lung, breast, prostate and ovarian, due to decreased Fra-1 and Survivin expression. The results also suggest ...

Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma

... with lenalidomide and dexamethasone in patients with relapsed multiple myeloma. Carfilzomib selectively blocks proteasome activity, causing apoptosis in cancer cells. In single agent Phase 1 studies carfilzomib has demonstrated encouraging anti-tumor activity and has been generally well tolerated. ...

Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma

... trials. About Genasense Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. ...

SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models

... SGI-1776 was identified as an orally available, potent and selective inhibitor of the PIM kinases. SGI-1776 induces cell cycle arrest, dose dependent apoptosis and a reduction in phospho-BAD levels in leukemia and lymphoma cell lines. Phospho-BAD is a direct substrate for PIM, and may serve as a useful in ...

Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma

... is developing MGd as an anti-cancer agent with a novel mechanism of action that is designed to selectively concentrate in tumors and induce apoptosis (programmed cell death). Its multifunctional mode of action, including its magnetic resonance imaging (MRI) detectability, provides the opportunity ...

Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma

... . About Genasense Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. ...

Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders

... . About Genasense Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. ...

Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors

... from South Texas Accelerated Research Therapeutics (START). In preclinical models of solid tumors, carfilzomib demonstrates activity and induces apoptosis of cancer cells when administered on a consecutive day dose schedule (day 1, day 2). Proteolix completed a 14-patient Phase 1b clinical trial ...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

... -- Poster presentation from 2:00 p.m. to 6:00 p.m. local time on Sunday, June 1, 2008. -- "Effect of a fully human anti-CD70 antibody on apoptosis and dephosphorylation of MAPK proteins in chronic lymphocytic leukemia" (Abstract #3073, Developmental Therapeutics: Immunotherapy ...

SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models

... for the creation of small molecule PIM kinase inhibitors. SGI-1776 was identified as a potent and selective inhibitor of the PIM kinases, inducing apoptosis and cell cycle arrest, thereby causing a reduction in phospho-BAD levels and enhancement of mTOR inhibition in vitro. Most notably, SGI-1776 ...

Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research

... and primary multiple myeloma cells. SNS-032 demonstrated broad, mechanism-based activity in the human myeloma cell lines and preferentially induced apoptosis in primary multiple myeloma cells versus peripheral blood mononuclear cells. In a series of studies examining SNS-032's mechanism of action and ...

EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting

... of the bulky breast cell line tumors grown in this model. In addition, the combination decreased angiogenesis and proliferation, and increased apoptosis as early as 4 days post treatment. Treatment with the combination also decreased the oncogenic proteins HIF-1alpha, pAKT, and pS6 ribosomal ...

Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors

... RDEA119 has shown potential as a potent and selective inhibitor of MEK, which is believed to play an important role in cancer cell proliferation, apoptosis and metastasis. Preclinical and clinical results suggest that RDEA119 has favorable properties, including oral dosing, excellent selectivity and ...